Adipotide vs Tirzepatide
A side-by-side research comparison of Adipotide and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Adipotide | Tirzepatide |
|---|---|---|
| Full name | Adipotide (FTPP / Prohibitin-Targeting Peptide) | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound (preclinical) | FDA Approved |
| Mechanism | A fusion of a prohibitin-targeting peptide and a pro-apoptotic sequence. It binds prohibitin on the vasculature that feeds white fat, inducing apoptosis of those blood vessels, which starves fat cells and causes them to be resorbed. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | ~2.6 kDa | 4,814 Da |
| Half-life | Short (hours) | 5 days (120 hours) |
| Bioavailability | Subcutaneous injection | High (SubQ ~80%) |
| Typical dose | Not established for human use | 2.5 mg → titrate up to 15 mg |
| Frequency | Research protocols only | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
Adipotide reported benefits
- Rapid targeted white-fat reduction (animal models)
- Weight loss without appetite suppression
- Reversal of metabolic markers in obese primates
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.